<DOC>
	<DOCNO>NCT00235391</DOCNO>
	<brief_summary>This open-label , non-randomized , multi-center trial design provide expand access deferasirox patient congenital disorder red blood cell chronic iron overload blood transfusion adequately treat locally approve iron chelators .</brief_summary>
	<brief_title>Expanded Access Deferasirox Patients With Congenital Disorders Red Blood Cells Chronic Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>Male female patient great equal 2 year age Documented congenital disorder red blood cell ( e.g. , βthalassemia major , sickle cell anemia , diamondblackfan anemia ) require ongoing blood transfusion Can adequately treat locally approve iron chelator due one follow reason : Documented noncompliance , define take less 50 % prescribed chelation therapy dose 12 month prior study entry Contraindications , unacceptable toxicity and/or document poor response locally approve iron chelators despite proper compliance History least 20 blood transfusion ( equivalent 100 mL/kg pack red blood cell ( PRBC ] ) Serum ferritin value great equal 1000 µg/L Ability comply studyrelated procedure , medication , evaluation Ongoing treatment another iron chelator ( Any iron chelation therapy must discontinue least 24 hour prior study entry . ) Patients meet eligibility criterion ongoing Novartis sponsor clinical study protocol deferasirox geographic access sit Patients unable tolerate ( unacceptable toxicity ) prior treatment deferasirox Serum creatinine upper limit normal screening . Patients ALT ≥ 500 U/L screening . Evidence chelationrelated cataract hear loss within 4 week prior baseline Pregnancy ( indicate serum βHCG pregnancy test screen female patient potential become pregnant ) patient breastfeed Patients treated systemic investigational drug within 4 week prior topical investigational drug within 7 day prior baseline visit Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Deferasirox</keyword>
	<keyword>Congenital Anemias</keyword>
	<keyword>Anemias</keyword>
	<keyword>Red Blood Cell Disorders</keyword>
	<keyword>Chronic Iron Overload</keyword>
	<keyword>Transfusional Iron Overload</keyword>
	<keyword>Iron Chelators</keyword>
	<keyword>Oral Iron Chelators</keyword>
	<keyword>Thalassemia</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Diamond Blackfan Anemia</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>ICL670A</keyword>
</DOC>